AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. BHC
  4. [Form 4] Bausch Health Companies Inc Insider Trading Activity

[Form 4] Bausch Health Companies Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Huntington Ingalls Industries (HII) filed an 8-K reporting a governance change under Item 5.02. Effective 29-Jul-2025, the Board elected Nick L. Stanage, former Chairman & CEO of Hexcel Corporation, as a director and increased the Board size from 12 to 13 members.

Stanage is assigned to the Audit Committee and the Governance & Policy Committee. He will receive an annual cash retainer of $120 k plus $25 k (Audit) and $20 k (Governance) committee fees, and an annual equity grant of $165 k in deferred stock units, all prorated for 2025.

No financial results, strategic transactions, or other material events were disclosed.

Huntington Ingalls Industries (HII) ha presentato un modulo 8-K comunicando una modifica nella governance ai sensi dell'Articolo 5.02. A partire dal 29 luglio 2025, il Consiglio di Amministrazione ha eletto Nick L. Stanage, ex Presidente e CEO di Hexcel Corporation, come nuovo direttore, aumentando il numero dei membri del Consiglio da 12 a 13.

Stanage 猫 stato assegnato al Comitato di Revisione e al Comitato per la Governance e le Politiche. Ricever脿 un compenso annuo in contanti di 120.000 $ 辫颈霉 25.000 $ per il Comitato di Revisione e 20.000 $ per il Comitato Governance, oltre a una concessione annuale di azioni differite per un valore di 165.000 $, tutto proporzionato per il 2025.

Non sono stati divulgati risultati finanziari, operazioni strategiche o altri eventi rilevanti.

Huntington Ingalls Industries (HII) present贸 un formulario 8-K informando un cambio en la gobernanza bajo el Punto 5.02. A partir del 29 de julio de 2025, la Junta eligi贸 a Nick L. Stanage, ex Presidente y CEO de Hexcel Corporation, como director y aument贸 el tama帽o de la Junta de 12 a 13 miembros.

Stanage fue asignado al Comit茅 de Auditor铆a y al Comit茅 de Gobernanza y Pol铆ticas. Recibir谩 una retenci贸n anual en efectivo de $120,000 尘谩蝉 $25,000 (Auditor铆a) y $20,000 (Gobernanza) en honorarios por comit茅, y una concesi贸n anual de acciones diferidas por valor de $165,000, todo prorrateado para 2025.

No se divulgaron resultados financieros, transacciones estrat茅gicas u otros eventos materiales.

Huntington Ingalls Industries (HII)電� 頃 5.02鞐� 霐半ジ 瓯半矂雱岇姢 氤�瓴� 靷暛鞚� 氤搓碃頃橂姅 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 2025雲� 7鞗� 29鞚茧秬搿� 鞚挫偓須岆姅 Nick L. Stanage 鞝� Hexcel Corporation 須岇灔 瓴� CEO毳� 鞚挫偓搿� 靹犾瀯頃橁碃 鞚挫偓須� 攴滊毳� 12氇呾棎靹� 13氇呾溂搿� 頇曤寑頄堨姷雼堧嫟.

厂迟补苍补驳别电� 臧愳偓鞙勋洂须�鞕赌 瓯半矂雱岇姢 氚� 鞝曥眳鞙勳洂須�鞐� 氚办爼霅橃棃鞀惦媹雼�. 攴鸽姅 鞐瓣皠 順勱笀 氤挫垬搿� 12毵� 雼煬鞕赌 臧愳偓鞙勋洂须� 靾橃垬耄� 2.5毵� 雼煬, 瓯半矂雱岇姢鞙勳洂須� 靾橃垬耄� 2毵� 雼煬毳� 氚涭溂氅�, 鞐瓣皠 16.5毵� 雼煬 靸侂嫻鞚� 鞚挫棸 欤检嫕 雼渼霃� 歆�旮夒皼鞀惦媹雼�. 氇摖 氤挫垬電� 2025雲� 旮办鞙茧 牍勲 氚半秳霅╇媹雼�.

鞛 鞁れ爜, 鞝勲灥鞝� 瓯半灅 霕愲姅 旮绊儉 欷戩殧頃� 靷贝鞚� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

Huntington Ingalls Industries (HII) a d茅pos茅 un rapport 8-K signalant un changement de gouvernance selon le point 5.02. 脌 compter du 29 juillet 2025, le conseil d'administration a 茅lu Nick L. Stanage, ancien pr茅sident-directeur g茅n茅ral de Hexcel Corporation, en tant que directeur et a port茅 la taille du conseil de 12 脿 13 membres.

Stanage a 茅t茅 nomm茅 au Comit茅 d'audit et au Comit茅 de gouvernance et des politiques. Il percevra une r茅mun茅ration annuelle en esp猫ces de 120 000 $ ainsi que des honoraires de comit茅 de 25 000 $ (audit) et 20 000 $ (gouvernance), et une attribution annuelle d鈥檃ctions diff茅r茅es d鈥檜ne valeur de 165 000 $, le tout au prorata pour 2025.

Aucun r茅sultat financier, transaction strat茅gique ou autre 茅v茅nement important n鈥檃 茅t茅 divulgu茅.

Huntington Ingalls Industries (HII) hat ein 8-K-Meldung eingereicht, die eine 脛nderung in der Unternehmensf眉hrung gem盲脽 Punkt 5.02 meldet. Mit Wirkung zum 29. Juli 2025 w盲hlte der Vorstand Nick L. Stanage, ehemaligen Vorsitzenden und CEO der Hexcel Corporation, als neues Vorstandsmitglied und erh枚hte die Gr枚脽e des Vorstands von 12 auf 13 Mitglieder.

Stanage wurde dem 笔谤眉蹿耻苍驳蝉补耻蝉蝉肠丑耻蝉蝉 und dem Ausschuss f眉r Governance & Richtlinien zugewiesen. Er erh盲lt eine j盲hrliche Barverg眉tung von 120.000 $ sowie Ausschussgeb眉hren von 25.000 $ (Pr眉fung) und 20.000 $ (Governance) sowie eine j盲hrliche Aktienzuteilung in H枚he von 165.000 $ in aufgeschobenen Aktienanteilen, alles anteilig f眉r 2025.

Es wurden keine Finanzergebnisse, strategischen Transaktionen oder andere wesentliche Ereignisse bekannt gegeben.

Positive
  • Seasoned leadership: Addition of former Hexcel CEO strengthens board aerospace expertise, relevant to HII鈥檚 defense programs.
  • Committee coverage: Placement on Audit and Governance Committees may enhance financial oversight and governance practices.
Negative
  • No financial data: Filing lacks earnings or outlook information, offering limited insight for valuation.
  • Incremental cost: Expanding the board to 13 increases annual director compensation expense, albeit immaterial.

Insights

TL;DR 鈥� Aerospace veteran joins HII board; modest governance enhancement with negligible near-term financial impact.

Nick Stanage brings three decades of aerospace and defense supply-chain experience, including a decade as Hexcel鈥檚 CEO, which should add depth to HII鈥檚 oversight of cost-intensive shipbuilding programs and advanced materials. Committee assignments (Audit, Governance) align with his operational and risk-management background. Compensation is standard for an S&P 500 peer and not material to P&L. The board expansion slightly raises governance costs (~$0.2 m annually) but may improve expertise mix. Overall, the filing is neutral; it signals continued focus on defense-aerospace synergies but offers no immediate earnings or strategic guidance.

Huntington Ingalls Industries (HII) ha presentato un modulo 8-K comunicando una modifica nella governance ai sensi dell'Articolo 5.02. A partire dal 29 luglio 2025, il Consiglio di Amministrazione ha eletto Nick L. Stanage, ex Presidente e CEO di Hexcel Corporation, come nuovo direttore, aumentando il numero dei membri del Consiglio da 12 a 13.

Stanage 猫 stato assegnato al Comitato di Revisione e al Comitato per la Governance e le Politiche. Ricever脿 un compenso annuo in contanti di 120.000 $ 辫颈霉 25.000 $ per il Comitato di Revisione e 20.000 $ per il Comitato Governance, oltre a una concessione annuale di azioni differite per un valore di 165.000 $, tutto proporzionato per il 2025.

Non sono stati divulgati risultati finanziari, operazioni strategiche o altri eventi rilevanti.

Huntington Ingalls Industries (HII) present贸 un formulario 8-K informando un cambio en la gobernanza bajo el Punto 5.02. A partir del 29 de julio de 2025, la Junta eligi贸 a Nick L. Stanage, ex Presidente y CEO de Hexcel Corporation, como director y aument贸 el tama帽o de la Junta de 12 a 13 miembros.

Stanage fue asignado al Comit茅 de Auditor铆a y al Comit茅 de Gobernanza y Pol铆ticas. Recibir谩 una retenci贸n anual en efectivo de $120,000 尘谩蝉 $25,000 (Auditor铆a) y $20,000 (Gobernanza) en honorarios por comit茅, y una concesi贸n anual de acciones diferidas por valor de $165,000, todo prorrateado para 2025.

No se divulgaron resultados financieros, transacciones estrat茅gicas u otros eventos materiales.

Huntington Ingalls Industries (HII)電� 頃 5.02鞐� 霐半ジ 瓯半矂雱岇姢 氤�瓴� 靷暛鞚� 氤搓碃頃橂姅 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 2025雲� 7鞗� 29鞚茧秬搿� 鞚挫偓須岆姅 Nick L. Stanage 鞝� Hexcel Corporation 須岇灔 瓴� CEO毳� 鞚挫偓搿� 靹犾瀯頃橁碃 鞚挫偓須� 攴滊毳� 12氇呾棎靹� 13氇呾溂搿� 頇曤寑頄堨姷雼堧嫟.

厂迟补苍补驳别电� 臧愳偓鞙勋洂须�鞕赌 瓯半矂雱岇姢 氚� 鞝曥眳鞙勳洂須�鞐� 氚办爼霅橃棃鞀惦媹雼�. 攴鸽姅 鞐瓣皠 順勱笀 氤挫垬搿� 12毵� 雼煬鞕赌 臧愳偓鞙勋洂须� 靾橃垬耄� 2.5毵� 雼煬, 瓯半矂雱岇姢鞙勳洂須� 靾橃垬耄� 2毵� 雼煬毳� 氚涭溂氅�, 鞐瓣皠 16.5毵� 雼煬 靸侂嫻鞚� 鞚挫棸 欤检嫕 雼渼霃� 歆�旮夒皼鞀惦媹雼�. 氇摖 氤挫垬電� 2025雲� 旮办鞙茧 牍勲 氚半秳霅╇媹雼�.

鞛 鞁れ爜, 鞝勲灥鞝� 瓯半灅 霕愲姅 旮绊儉 欷戩殧頃� 靷贝鞚� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

Huntington Ingalls Industries (HII) a d茅pos茅 un rapport 8-K signalant un changement de gouvernance selon le point 5.02. 脌 compter du 29 juillet 2025, le conseil d'administration a 茅lu Nick L. Stanage, ancien pr茅sident-directeur g茅n茅ral de Hexcel Corporation, en tant que directeur et a port茅 la taille du conseil de 12 脿 13 membres.

Stanage a 茅t茅 nomm茅 au Comit茅 d'audit et au Comit茅 de gouvernance et des politiques. Il percevra une r茅mun茅ration annuelle en esp猫ces de 120 000 $ ainsi que des honoraires de comit茅 de 25 000 $ (audit) et 20 000 $ (gouvernance), et une attribution annuelle d鈥檃ctions diff茅r茅es d鈥檜ne valeur de 165 000 $, le tout au prorata pour 2025.

Aucun r茅sultat financier, transaction strat茅gique ou autre 茅v茅nement important n鈥檃 茅t茅 divulgu茅.

Huntington Ingalls Industries (HII) hat ein 8-K-Meldung eingereicht, die eine 脛nderung in der Unternehmensf眉hrung gem盲脽 Punkt 5.02 meldet. Mit Wirkung zum 29. Juli 2025 w盲hlte der Vorstand Nick L. Stanage, ehemaligen Vorsitzenden und CEO der Hexcel Corporation, als neues Vorstandsmitglied und erh枚hte die Gr枚脽e des Vorstands von 12 auf 13 Mitglieder.

Stanage wurde dem 笔谤眉蹿耻苍驳蝉补耻蝉蝉肠丑耻蝉蝉 und dem Ausschuss f眉r Governance & Richtlinien zugewiesen. Er erh盲lt eine j盲hrliche Barverg眉tung von 120.000 $ sowie Ausschussgeb眉hren von 25.000 $ (Pr眉fung) und 20.000 $ (Governance) sowie eine j盲hrliche Aktienzuteilung in H枚he von 165.000 $ in aufgeschobenen Aktienanteilen, alles anteilig f眉r 2025.

Es wurden keine Finanzergebnisse, strategischen Transaktionen oder andere wesentliche Ereignisse bekannt gegeben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
LEUNG SANDRA
(Last) (First) (Middle)
400 SOMERSET CORPORATE BLVD.
(Street)
BRIDGEWATER NJ 08807
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Bausch Health Companies Inc. [ BHC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares, No Par Value 07/25/2025 A 30,149(1) A $0 30,149 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents Restricted Share Units ("RSUs"), each representing a contingent right to receive one Common Share, no par value, of Bausch Health Companies Inc., which will vest immediately before the 2026 Annual Meeting of Shareholders.
/s/ Brianna M. Cetrulo, attorney-in-fact 07/29/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

Who joined Huntington Ingalls Industries' board on 29-Jul-2025?

Former Hexcel Corporation CEO Nick L. Stanage was elected as a director.

What committees will Nick Stanage serve on at HII?

He was appointed to the Audit Committee and the Governance & Policy Committee.

How much compensation will the new HII director receive?

Annual cash retainer of $120 k, plus $25 k (Audit) and $20 k (Governance) retainers, and $165 k in deferred stock units, all prorated for 2025.

Did Huntington Ingalls disclose any financial results in this 8-K?

No. The filing solely covers the board appointment and contains no earnings or guidance.

Why did HII increase its board size to 13 members?

The board expansion accommodates the addition of Nick Stanage; no further rationale was provided.
Stock BHC logo
Bausch Health Companies Inc

NYSE:BHC

BHC Rankings

#2521 Ranked by Market Cap
N/A Ranked by Dividends

BHC Latest News

Jul 29, 2025
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
Jul 28, 2025
Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand
Jul 24, 2025
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
Jul 10, 2025
CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs
Jul 10, 2025
Bausch Health Appoints New Chief Accounting Officer

BHC Latest SEC Filings

Jul 29, 2025
[Form 4] Bausch Health Companies Inc Insider Trading Activity
Jul 29, 2025
[Form 3] Bausch Health Companies Inc Initial Statement of Beneficial Ownership
Jul 29, 2025
[Form 3] Bausch Health Companies Inc Initial Statement of Beneficial Ownership
Jul 29, 2025
[SC TO-C] Bausch Health Companies Inc Tender Offer Communication
Jul 29, 2025
[8-K] Bausch Health Companies Inc Reports Material Event

BHC Stock Data

2.50B
323.52M
11.31%
70.94%
1.75%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Canada
QUEBEC